LEXINGTON, Mass., July 10,
2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of emavusertib
(CA-4948), an orally available, small molecule IRAK4 inhibitor,
today announced that James Dentzer,
President and Chief Executive Officer of Curis, will present at the
Jones Healthcare Seaside Summit 2024 on July 15, 2024 at
8:00 a.m. PT (11:00 a.m. ET). A live webcast and archived
replay will be available and can be accessed here or on
the Events & Presentations section of Curis's website.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor.
Emavusertib is currently undergoing testing in the Phase 1/2
TakeAim Lymphoma study in patients with relapsed/refractory primary
central nervous system lymphoma (PCNSL) in combination with the BTK
inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim
Leukemia study in patients with relapsed/refractory acute myeloid
leukemia (AML) and relapsed/refractory high risk myelodysplastic
syndrome (hrMDS) with either a FLT3 mutation or a splicing factor
mutation (U2AF1 or SF3B2), and as a frontline combination therapy
with azacitidine and venetoclax in patents with AML. Emavusertib
has received Orphan Drug Designation from the U.S. Food and Drug
Administration for the treatment of AML and MDS. Curis,
through its 2015 collaboration with Aurigene, has the exclusive
license to emavusertib (CA-4948). Curis licensed its rights to
Erivedge® to Genentech, a member of the Roche Group, under which
they are commercializing Erivedge® for the treatment of advanced
basal cell carcinoma. For more information, visit Curis's website
at www.curis.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conference-in-july-302192752.html
SOURCE Curis, Inc.